Ines Martins writing for Lymphoma News Today reports that Sarah Cannon Research Institute in collaboration with Tennessee Oncology, is conducting a Phase ½ trial evaluating Loxo Oncology’s BTK inhibitor LOXO-305 in leukemia and lymphoma patients who failed or were intolerant to approved BTK inhibitors.

Source: Lymphoma News Today

Pin It on Pinterest